ADCT - Immunomedics Positive Cancer Data And Other News: The Good Bad And Ugly Of Biopharma
Immunomedics Reports Positive Phase 3 Data for Cancer Drug
Immunomedics Inc. (IMMU) reported that its confirmatory Phase 3 ASCENT study met its primary endpoint. The trial aimed to test Trodelvy for treating brain metastasis negative patients with mTNBC who have previously received at least two prior therapies for metastatic disease. Trodelvy is the first antibody-drug conjugate to show improved clinical outcomes in such patients.
Trodelvy showed a statistically significant improvement in the primary endpoint pertaining progression free survival compared to chemotherapy. The median PFS for treatment arm was 5.6 months while the control